Abstract:Objective: This study aimed to explore the influence of tangeretin on the TXNIP/NLRP3 signaling pathway in regulating cell pyroptosis in severe pneumonia rats.Methods: Sprague-Dawley rats were divided into control group, severe pneumonia group, low-dose tangeretin group, high-dose tangeretin group, high-dose tangeretin + pcDNA group, and high-dose tangeretin + pcDNA-TXNIP (TXNIP activator) group, with 12 rats in each group. Except for the control group, all other groups were induced to establish a severe pneumonia rat model by tracheal instillation of Klebsiella pneumoniae. Drug administration began immediately after successful modeling and continued for 4 weeks. Lung function parameters including peak expiratory flow (PEF) and forced vital capacity (FVC) were monitored using an animal lung function meter. Levels of interleukin (IL)-1β and IL-18 in bronchoalveolar lavage fluid were measured by ELISA. Changes in lung wet-to-dry weight ratio were evaluated. Lung histopathological changes were assessed by HE staining. Cell pyroptosis in lung tissues was detected using propidium iodide (PI) staining. Expression levels of TXNIP, NLRP3, cleaved caspase-1, and N-terminal fragment of gasdermin D (GSDMD-N) in lung tissues were analyzed by Western blot.Results: Compared with the control group, rats in the severe pneumonia group showed severe lung tissue damage, decreased PEF and FVC, increased levels of IL-1β and IL-18 in bronchoalveolar lavage fluid, increased lung wet-to-dry weight ratio, elevated cell pyroptosis rate in lung tissues, and increased expression of TXNIP, NLRP3, cleaved caspase-1, and GSDMD-N proteins (P<0.05). Compared with the severe pneumonia group, rats in the low-dose tangeretin and high-dose tangeretin groups exhibited improved lung tissue damage, increased PEF and FVC, decreased levels of IL-1β and IL-18 in bronchoalveolar lavage fluid, decreased lung wet-to-dry weight ratio, reduced cell pyroptosis rate in lung tissues, and decreased expression of TXNIP, NLRP3, cleaved caspase-1, and GSDMD-N proteins (P<0.05). The protective effect of high-dose tangeretin on severe pneumonia was reversed by pcDNA-TXNIP.Conclusion: Tangeretin may inhibit inflammation and cell pyroptosis in severe pneumonia rats by blocking the TXNIP/NLRP3 pathway.
[1] 马娜,金雨舟,刘福菁,等.乳酸脱氢酶白蛋白比值对重症肺炎患者并发弥散性血管内凝血的预测价值[J].中国呼吸与危重监护杂志,2023,22(12):845-851.
[2] Luo S,Gan L,Liu S,et al.The synergistic reduning and cefmetazole sodium treatment of severe pneumonia is mediated by the AhR-Src-STAT3 pathway[J].Thorac Dis,2022,14(2):474-493.
[3] Haggag YA,El-Ashmawy NE,Okasha KM.Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?[J].Med Hypotheses,2020,144(1):109957-109960.
[4] 王亚静,张静,宋卫卫,等.大黄素通过调控ROS/TXNIP/NLRP3轴介导的细胞焦亡途径减轻重症肺炎大鼠肺损伤[J].中国病理生理杂志,2021,37(7):1240-1245.
[5] Chen D,Cao L,Li W.Etiological and clinical characteristics of severe pneumonia in pediatric intensive care unit (PICU)[J].BMC Pediatr,2023,23(1):362-372.
[6] Bao XL,Tang N,Wang YZ.Severe klebsiella pneumoniae pneumonia complicated by acute intra-abdominal multiple arterial thrombosis and bacterial embolism:a case report[J].World Clin Cases,2022,10(30):11101-11110.
[7] Snyder AG,Oberst A.The antisocial network:cross talk between cell death programs in host defense[J].Annu Rev Immunol,2021,39(1):77-101.
[8] Xu JJ,Liu Z,Tang W,et al.Tangeretin from citrus reticulate inhibits respiratory syncytial virus replication and associated inflammation in vivo[J].Agric Food Chem,2015,63(43):9520-9527.
[9] Liu LL,Li FH,Zhang Y,et al.Tangeretin has anti-asthmatic effects via regulating PI3K and notch signaling and modulating Th1/Th2/Th17 cytokine balance in neonatal asthmatic mice[J].Braz Med Biol Res,2017,50(8):1-13.
[10] Wu X,Wu L,Wu Y,et al.Heme oxygenase-1 ameliorates endotoxin-induced acute lung injury by modulating macrophage polarization via inhibiting TXNIP/NLRP3 inflammasome activation[J].Free Radic Biol Med,2023,194(1):12-22.
[11] He G,Chen K,Wang H,et al.Fudosteine attenuates acute lung injury in septic mice by inhibiting pyroptosis via the TXNIP/NLRP3/GSDMD pathway[J].Eur Pharmacol,2022,926(1):175047-175057.